Positions

Overview

  • Dr. Elson received his M.D. from Washington University in St. Louis, trained in Internal Medicine at New York Hospital/Cornell, then did his Gastroenterology fellowship at the University of Chicago.  After doing full-time research in immunology at N.I.H., he joined the Faculty of the Division of Gastroenterology at the Medical College of Virginia.  He moved to the University of Alabama at Birmingham to become Director of the Division of Gastroenterology and Hepatology,  and subsequently served as Vice-Chair for Research in the Department of  Medicine.  He holds the Basil I. Hirschowitz Chair in Gastroenterology and is an active consultant in immune-mediated intestinal disorders. Additionally, Dr. Elson has received the "Best Doctors in America" recognition from 1998 to current. The author of numerous peer-reviewed manuscripts, reviews, and book chapters, Dr. Elson as held major positions in national organizations, and has served on a number of advisory boards, including the Advisory Council of the National Institute of Diabetes and Digestive and Kidney Diseases.  He has been elected to many of the most outstanding professional societies in the field of academic medicine and has a long history of service to the Society for Mucosal Immunology for which he is a co-founder and past president. Dr.Elson is a collaborative investigator in the Mucosal HIV and Immunobiology Center (MHIC) at UAB. 
The central focus of the Elson laboratory is on the regulation of mucosal immune responses, particularly the mucosal immune response to the microbiota, which represent the largest mass of antigen encountered by the immune system. The cellular and molecular mechanisms that maintain mucosal immune homeostasis are being defined. When these mechanisms fail, pathogenic effector T cells are generated that result in colitis. Dr. Elson and co-workers have cloned a set of immunodominant antigens of the microbiota that stimulate such pathogenic T cells and result in inflammatory bowel disease. Among these cloned antigens, previously unknown bacterial flagellins have emerged as a major cluster. Seroreactivity to these flagellins is found in multiple experimental models of colitis in mice and in half of patients with Crohn’s disease. These antigens drive a newly described CD4 T cell effector subset making IL-17 (Th17) which appears to be responsible for disease progression. A T cell receptor transgenic mouse reactive to the flagellins has been generated and is being used to study the innate and adaptive immune response to microbiota antigens. A second major effort is in the identification of T reg cells in the intestine that recognize microbial antigens and maintain homeostasis. The mechanisms whereby such cells are induced are being defined and the application of these cells to prevent or treat intestinal inflammation is being tested.
  • Selected Publications

    Academic Article

    Year Title Altmetric
    2019 Depletion of dietary aryl hydrocarbon receptor ligands alters microbiota composition and function 2019
    2019 Challenges in IBD Research: Pragmatic Clinical Research 2019
    2019 Decreased Fecal Bacterial Diversity and Altered Microbiome in Children Colonized With Clostridium difficile 2019
    2019 Akkermansia muciniphila is permissive to arthritis in the K/BxN mouse model of arthritis 2019
    2018 Expanded TCRβ CDR3 clonotypes distinguish Crohn’s disease and ulcerative colitis patients 2018
    2018 Adaptive immune education by gut microbiota antigens 2018
    2017 Moms, babies, and bugs in immune development 2017
    2017 CBirTox is a selective antigen-specific agonist of the Treg-IgA-microbiota homeostatic pathway 2017
    2017 Selective induction of homeostatic Th17 cells in the murine intestine by cholera toxin interacting with the microbiota 2017
    2017 Dysregulation of Systemic and Mucosal Humoral Responses to Microbial and Food Antigens as a Factor Contributing to Microbial Translocation and Chronic Inflammation in HIV-1 Infection 2017
    2017 Helicobacter species are potent drivers of colonic T cell responses in homeostasis and inflammation 2017
    2017 Microbial antigen encounter during a preweaning interval is critical for tolerance to gut bacteria 2017
    2016 Elucidating the Role of the Interleukin-10 Receptor in Mucosal Inflammation Uncovers a Potential Treatment for Infantile Inflammatory Bowel Disease 2016
    2016 Abdominal Pain With an Unusual Radiographic Image 2016
    2016 Commensal A4 bacteria inhibit intestinal Th2-cell responses through induction of dendritic cell TGF-β production 2016
    2016 Deletion of the toll-like receptor 5 gene per se does not determine the gut microbiome profile that induces metabolic syndrome: Environment trumps genotype 2016
    2015 Human seroreactivity to gut microbiota antigens 2015
    2015 Group 3 innate lymphoid cells mediate intestinal selection of commensal bacteria-specific CD4+ T cells 2015
    2015 Host-microbiota interactions in the intestine 2015
    2015 TGF-β converts Th1 cells into Th17 cells through stimulation of Runx1 expression 2015
    2015 Immunological Biomarkers in Postinfectious Irritable Bowel Syndrome 2015
    2015 Interleukin (IL)-21 promotes intestinal IgA response to microbiota 2015
    2014 Altered microbiota associated with abnormal humoral immune responses to commensal organisms in enthesitis-related arthritis 2014
    2014 Lloyd F. Mayer, MD: A remembrance 2014
    2014 Downregulation of microRNA-107 in intestinal CD11c+ myeloid cells in response to microbiota and proinflammatory cytokines increases IL-23p19 expression 2014
    2014 Microbiota activation and regulation of innate and adaptive immunity 2014
    2014 Tlr4 regulates IFN-γ and IL-17 production by both thymic and induced Foxp3+Tregsduring intestinal inflammation 2014
    2013 Clostridium difficile carriage and serum antitoxin responses in children with inflammatory bowel disease 2013
    2013 ERK differentially regulates Th17- and Treg-cell development and contributes to the pathogenesis of colitis 2013
    2013 Innate lymphoid cells regulate CD4 + T-cell responses to intestinal commensal bacteria 2013
    2013 The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin 2013
    2013 The intestinal microbiota modulates the anticancer immune effects of cyclophosphamide 2013
    2012 Th17 cells upregulate polymeric Ig receptor and intestinal IgA and contribute to intestinal homeostasis 2012
    2012 Acute gastrointestinal infection induces long-lived microbiota-specific T cell responses 2012
    2012 Reciprocal interactions of the intestinal microbiota and immune system 2012
    2012 Host-microbiota interactions in inflammatory bowel disease 2012
    2012 Biomarkers of therapeutic response in the IL-23 pathway in inflammatory bowel disease 2012
    2012 So Long, Folks 2012
    2012 Regulation of Toll-like receptor 5 gene expression and function on mucosal dendritic cells 2012
    2012 Exam 1: Alternative Therapeutic Approaches to Chronic Proton Pump Inhibitor Treatment 2012
    2011 Microbiota downregulates dendritic cell expression of miR-10a, which targets IL-12/IL-23p40 2011
    2011 Exam 1: Cirrhosis With Refractory Ascites: Serial Large Volume Paracentesis, TIPS, or Transplantation? 2011
    2011 Humoral immune response to keyhole limpet haemocyanin, the protein carrier in cancer vaccines 2011
    2011 CME Activities–Exams 1 and 2 2011
    2011 Th17 cells induce colitis and promote Th1 cell responses through IL-17 induction of innate IL-12 and IL-23 production 2011
    2011 Treg cell-IgA axis in maintenance of host immune homeostasis with microbiota 2011
    2011 Exam 1: How Do I Handle the Patient With Noncardiac Chest Pain? 2011
    2011 Experimental inflammatory bowel disease: Insights into the host-microbiota dialog 2011
    2011 Adaptive immunity in the host-microbiota dialog 2011
    2011 CME Activities#226;#128;#147;Exams 1 (2011-01) 2011
    2011 IL-12 converts Foxp3(+) regulatory T cells to Foxp3(+)IFN-γ(+) T cells with inhibitory functions during induction of colitis 2011
    2011 Interleukin-12 converts Foxp3+ regulatory T cells to interferonγ-producing Foxp3+ T cells that inhibit colitis 2011
    2010 Generation of mucosal dendritic cells from bone marrow reveals a critical role of retinoic acid 2010
    2010 Exam 2: Incidence of Bleeding Following Invasive Procedures in Patients With Thrombocytopenia and Advanced Liver Disease 2010
    2010 Exam 2: A 41-Year-Old Woman With Abdominal Complaints: Is It Food Allergy or Food Intolerance? How to Tell the Difference 2010
    2010 Microbiota innate stimulation is a prerequisite for T cell spontaneous proliferation and induction of experimental colitis (The Journal of Experimental Medicine (2010) 207, 6 (1321-1332)) 2010
    2010 Enterorhabdus caecimuris sp. nov., a member of the family Coriobacteriaceae isolated from a mouse model of spontaneous colitis, and emended description of the genus Enterorhabdus Clavel et al. 2009 2010
    2010 Microbiota innate stimulation is a prerequisite for T cell spontaneous proliferation and induction of experimental colitis 2010
    2010 Exam 2: Factors That Predict Outcome of Abdominal Operations in Patients With Advanced Cirrhosis 2010
    2010 Microbiota dual-faceted player in experimental colitis 2010
    2009 A dominant, coordinated T regulatory cell-IgA response to the intestinal microbiota 2009
    2009 Curcumin induces the tolerogenic dendritic cell that promotes differentiation of intestine-protective regulatory T cells 2009
    2009 Microbial induction of inflammatory bowel disease associated gene TL1A (TNFSF15) in antigen presenting cells 2009
    2009 TGF-β promotes Th17 cell development through inhibition of SOCS3 2009
    2009 Late Developmental Plasticity in the T Helper 17 Lineage 2009
    2009 Linkage of Crohn's disease-related serological phenotypes: NFKB1 haplotypes are associated with anti-CBiri and ASCA, and show reduced NF-κB activation 2009
    2008 Enhanced CBir1-specific innate and adaptive immune responses in Crohn's disease 2008
    2008 III. Report of adaptive and regulatory immune responses workgroup 2008
    2008 X. Challenges update workgroups 2008
    2008 Peyer's patches as the inductive site for IgA responses 2008
    2007 Molecular mechanism of lipopolysaccharide-induced SOCS-3 gene expression in macrophages and microglia 2007
    2007 Perspectives on mucosal vaccines: Is mucosal tolerance a barrier? 2007
    2007 Isolation of flagellated bacteria implicated in Crohn's disease 2007
    2007 A novel role for defensins in intestinal homeostasis: Regulation of IL-1β secretion 2007
    2007 Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations 2007
    2007 CCFA microbial-host interactions workshop: Highlights and key observations 2007
    2007 CCFA host-microbial interactions workshop: highlights and key observations 2007
    2007 Fenofibrate Represses Interleukin-17 and Interferon-γ Expression and Improves Colitis in Interleukin-10-Deficient Mice 2007
    2007 Monoclonal Anti-Interleukin 23 Reverses Active Colitis in a T Cell-Mediated Model in Mice 2007
    2006 Alterations of T lymphocytes in inflammatory bowel diseases 2006
    2006 From Cheese to Pharma: A Designer Probiotic for IBD 2006
    2006 Transforming growth factor-β induces development of the T H17 lineage 2006
    2006 Serum immune responses predict rapid disease progression among children with Crohn's disease: Immune responses predict disease progression 2006
    2006 From Cheese to Pharma: A Designer Probiotic for IBD 2006
    2006 Molecular approaches to the role of the microbiota in inflammatory bowel disease 2006
    2006 Tight Mucosal Compartmentation of the Murine Immune Response to Antigens of the Enteric Microbiota 2006
    2005 Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota 2005
    2005 Animal models of intestinal inflammation: Ineffective communication between coalition members 2005
    2005 National Institutes of Health Consensus Development Conference statement on Celiac Disease, June 28-30, 2004 2005
    2005 Immune response versus mucosal tolerance to mucosally administered antigens 2005
    2005 Generation of antigen-specific, Foxp3-expressing CD4+ regulatory T cells by inhibition of APC proteosome function 2005
    2005 A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-α, in patients with corticosteroid-dependent Crohn's disease 2005
    2005 Animal models of intestinal inflammation: ineffective communication between coalition members 2005
    2005 Antibodies to CBir1 flagellin define a unique response that is associated independently with complicated Crohn's disease 2005
    2005 Cdcs1, a major colitogenic locus in mice, regulates innate and adaptive immune response to enteric bacterial antigens 2005
    2005 Experimental models of inflammatory bowel disease reveal innate, adaptive, and regulatory mechanisms of host dialogue with the microbiota 2005
    2004 Regulatory T cell suppression and anergy are differentially regulated by proinflammatory cytokines produced by TLR-activated dendritic cells 2004
    2004 Anti-interleukin-12 antibody for active Crohn's disease 2004
    2004 Refined histopathologic scoring system improves power to detect colitis QTL in mice 2004
    2004 New developments in experimental models of inflammatory bowel disease 2004
    2004 Bacterial flagellin is a dominant antigen in Crohn disease 2004
    2004 Early upregulation of T cell IL-10 production plays an important role in oral tolerance induction 2004
    2004 Early upregulation of T cell IL-10 production plays an important role in oral tolerance induction 2004
    2004 Gene disruption and immunity in experimental colitis 2004
    2004 New developments in experimental inflammatory bowel disease 2004
    2004 Oral tolerance in humans: Failure to suppress an existing immune response by oral antigen administration 2004
    2004 Oral tolerance in humans: failure to suppress an existing immune response by oral antigen administration 2004
    2004 Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs 2004
    2004 Regulation of gene expression in inflammatory bowel disease and correlation with IBD drugs: screening by DNA microarrays. 2004
    2003 Challenges in IBD research: Updating the scientific agendas 2003
    2003 Probiotics and immune regulation of inflammatory bowel diseases 2003
    2003 Probiotics and immune regulation of inflammatory bowel diseases. 2003
    2002 Bacterial-reactive T regulatory cells inhibit pathogenic immune responses to the enteric flora 2002
    2002 Understanding immune-microbial homeostasis in intestine 2002
    2002 Genes, microbes, and T cells - New therapeutic targets in Crohn's disease 2002
    2002 T helper 1 and T helper 2 cells are pathogenic in an antigen-specific model of colitis 2002
    2001 A major quantitative trait locus on chromosome 3 controls colitis severity in IL-10-deficient mice 2001
    2001 Effects of cholera toxin on macrophage production of co-stimulatory cytokines. 2001
    2001 Immno-bacterial homeostasis in the gut: new insights into an old enigma 2001
    2001 Immuno-bacterial homeostasis in the gut: New insights into an old enigma 2001
    2001 Mechanisms of immune tolerance to food antigens in humans 2001
    2000 Heritable susceptibility for colitis in mice induced by IL-10 deficiency 2000
    2000 Colitis induced by enteric bacterial antigen-specific CD4+ T cells requires CD40-CD40 ligand interactions for a sustained increase in mucosal IL-12 2000
    2000 Commensal bacteria as targets in Crohn's disease 2000
    2000 Genes, bugs, and T cells : New Insights into the Pathogenesis of Inflammatory Bowel Disease 2000
    2000 Mice deficient in Th1- and Th2-type cytokines develop distinct forms of hapten-induced colitis 2000
    2000 Recombinant human interleukin 10 in the treatment of patients with mild to moderately active Crohn's disease 2000
    2000 The C3H/HeJBir mouse model: A high susceptibility phenotype for colitis 2000
    1999 Memory/effector T cells in TCR transgenic mice develop via recognition of enteric antigens by a second, endogenous TCR 1999
    1999 Differential homing commitments of antigen-specific T cells after oral or parenteral immunization in humans 1999
    1999 Genetic analysis of susceptibility to dextran sulfate sodium-induced colitis in mice 1999
    1999 Intestinal IgA: Novel views on its function in the defence of the largest mucosal surface 1999
    1998 Role of mucosal adjuvants in mucosal immunization 1998
    1998 Mucosal immunology and the eye 1998
    1998 pANCA represents a cross-reactivity to enteric bacterial antigens 1998
    1998 CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: increased T helper cell type 1 response and ability to transfer disease. 1998
    1998 CD4+ T cells reactive to enteric bacterial antigens in spontaneously colitic C3H/HeJBir mice: Increased T helper cell type 1 response and ability to transfer disease 1998
    1998 Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis 1998
    1998 Experimental models to study molecular mechanisms underlying intestinal disease. Proceedings of Symposium Intestinal Plasticity in Health and Disease 1998
    1998 Experimental models to study molecular mechanisms underlying intestinal inflammation 1998
    1998 Regional differences in L-selectin expression in murine intestinal lymphocytes 1998
    1997 Spontaneously Colitic C3H/HeJBir Mice Demonstrate Selective Antibody Reactivity to Antigens of the Enteric Bacterial Flora 1997
    1997 The Mucosal Adjuvanticity of Cholera Toxin Involves Enhancement of Costimulatory Activity by Selective Up-Regulation of B7.2 Expression 1997
    1997 Advances in mucosal immunity 1997
    1997 Strong mucosal adjuvanticity of cholera toxin within lipid particles of a new multiple emulsion delivery system for oral immunization 1997
    1997 In defense of mucosal surfaces: Regulation and manipulation of the mucosal immune system 1997
    1997 Single-cell analyses of CD4+ T cells from αβ T cell receptor-transgenic mice: A distinct mucosal cytokine phenotype in the absence of transgene-specific antigen 1997
    1997 Induced mutant models of IBD: The role of genes, bacteria and immunity 1997
    1997 Multiple doses of intravenous interleukin 10 in steroid-refractory Crohn's disease 1997
    1996 Cholera toxin enhances costimulatory activity of macrophages by differentially regulating b7.1 and b7.2 expression 1996
    1996 Differences in phenotypes and activation markers in different compartments of the intestine 1996
    1996 In vivo analysis of CD4+ T cell responses to oral immunization 1996
    1996 Kinetics of cytokine expression during healing of acute colitis in mice 1996
    1996 Mucosally activated circulating human T-cells express the gut homing receptor α4β7 1996
    1996 Multiple mechanisms of oral tolerance to food antigens in humans 1996
    1996 Tolerization of ovalbumin-specific αβ-tcr transgenic cells in adoptively transferred mice by the feeding of ovalbumin 1996
    1996 Identification of an immunodominant T cell epitope on cholera toxin 1996
    1996 The effects of immunosuppressive agents on cytokines 1996
    1996 Persistent Clonal Expansions of Peripheral Blood CD4+ Lymphocytes in Chronic Inflammatory Bowel Disease 1996
    1996 Hapten-Induced Model of Murine Inflammatory Bowel Disease: Mucosal Immune Responses and Protection by Tolerance 1996
    1996 Kinetics of cytokine expression during healing of acute colitis in mice 1996
    1996 Kinetics of cytokine expression during healing of acute colitis in mice. 1996
    1996 An oral preparation of mesalamine as long-term maintenance therapy for ulcerative colitis. A randomized, placebo-controlled trial 1996
    1996 Immunology of inflammatory bowel disease 1996
    1996 Immunology of inflammatory bowel disease 1996
    1996 Induction of tolerance in humans. Effectiveness of oral and nasal immunization routes 1996
    1996 Induction of tolerance in humans: Effectiveness of oral and nasal immunization routes 1996
    1996 Oral antigen delivery via a multiple emulsion system enhances oral tolerance 1996
    1996 Oral-antigen delivery by way of a multiple emulsion system enhances oral tolerance 1996
    1996 Persistent clonal expansions of CD4+ lymphocytes implicate specific chronic antigen exposure in the pathogenesis of inflammatory bowel disease 1996
    1996 Regulation of mucosal immune responses - The missing link in IBD? 1996
    1996 The basis of current and future therapy for inflammatory bowel disease 1996
    1996 The effects of immunosuppressive agents on cytokines 1996
    1996 Why doesn't cyclosporine work in Crohn's disease? 1996
    1995 Differences in intraepithelial lymphocyte T cell subsets isolated from murine small versus large intestine 1995
    1995 Experimental models of inflammatory bowel disease 1995
    1995 Intraperitoneal administration of tetanus toxoid elicits a specific response of antibody-secreting cells in the peritoneal cavity 1995
    1995 Intraperitoneal administration of tetanus toxoid elicits a specific responses of antibody-secreting cells in the peritoneal cavity 1995
    1995 Morphologic and functional alterations of mucosal T cells by cholera toxin and its B subunit 1995
    1995 Oral tolerance in humans: T cell but not B cell tolerance to a soluble protein antigen 1995
    1995 Oral tolerance in humans: T cell but not B cell tolerance to a soluble protein antigen 1995
    1995 The effect of immunosuppressive agents on monocyte generation and cytokine expression 1995
    1995 Transient protein S deficiency associated with cerebral venous thrombosis in active ulcerative colitis 1995
    1994 Oral tolerance in humans: T cell but not B cell tolerance after antigen feeding 1994
    1994 Dextran sulfate sodium-induced colitis occurs in severe combined immunodeficient mice 1994
    1994 Intraperitoneal immunization of human subjects with tetanus toxoid induces specific antibody-secreting cells in the peritoneal cavity and in the circulation, but fails to elicit a secretory IgA response 1994
    1994 Spontaneous, heritable colitis in a new substrain of C3H/HeJ mice 1994
    1993 Helper t cell subsets for immunoglobulin a responses: Oral inmaunization with tetanus toxoid and cholera toxinn as adjuvant selectively induces th2 cells in mucosa associated tissues 1993
    1993 Low-dose oral methotrexate in refractory inflammatory bowel disease 1993
    1993 NEW PERSPECTIVES IN MUCOSAL IMMUNITY WITH EMPHASIS ON VACCINE DEVELOPMENT 1993
    1993 New perspectives in mucosal immunity with emphasis on vaccine development. 1993
    1993 Comparative effectiveness of the cholera toxin B subunit and alkaline phosphatase as carriers for oral vaccines 1993
    1993 Enhancing effect of cholera toxin on interleukin-6 secretion by IEC-6 intestinal epithelial cells: Mode of action and augmenting effect of inflammatory cytokines 1993
    1993 Inhibition of murine T cell activation by cholera toxin B subunit is not mediated through the phosphatidylinositol second messenger system 1993
    1993 Optimizing oral vaccines: Induction of systemic and mucosal B-cell and antibody responses to tetanus toxoid by use of cholera toxin as an adjuvant 1993
    1993 Oral tolerance and autoimmunity 1993
    1993 Reduction in oral immunogenicity of cholera toxin B subunit by N-terminal peptide addition 1993
    1992 Cells and cytokines in mucosal immunity and inflammation 1992
    1992 Cholera toxin as a mucosal adjuvant: Effects of H-2 major histocompatibility complex and lps genes 1992
    1991 Interleukin-10 and Counting. Selected Summary 1991
    1991 Interleukin-10 and counting ... 1991
    1991 Preface 1991
    1990 Cyclosporine in Crohn's disease-Low doses won't do it 1990
    1990 Activation of cholera toxin-specific T cells in vitro 1990
    1990 Cyclosporine in Crohn's Disease-- Low Doses Won't Do It. Selected Summary 1990
    1990 Cytokines can make you sick - or keep you well. Selected Summary. 1990
    1990 Cytokines can make you sick-Or keep you well 1990
    1990 Cytokines can make you sick-Or keep you well 1990
    1990 Do organ-specific suppressor T cells prevent autoimmune gastritis? 1990
    1990 Primary Biliary Cirrhosis in a Mouse? Selected Summary 1990
    1990 Primary biliary cirrhosis in a mouse? 1990
    1989 Regulation of IgA synthesis and immune response by T cells and interleukins 1989
    1989 Interleukin-5 stimulates IgA secretion. Selected Summary. 1989
    1989 Interleukin-5 stimulates immunoglobulin a secretion 1989
    1989 Regulation of IgA Synthesis and Immune Response by T Cells and Interleukins 1989
    1989 Specialized receptors for antigens on gut epithelial T cells 1989
    1989 Specialized receptors for antigens on gut epithelial T cells. Selected Summary 1989
    1988 A method of obtaining, processing, and analyzing human intestinal secretions for antibody content 1988
    1988 Collagen content and types in normal intestine and in the strictures of Crohn's disease 1988
    1988 Collagen content and types in the intestinal strictures of Crohn's disease 1988
    1988 Intestinal IgA system 1988
    1988 Regulatory activity of the human CD8+ cell subset: a comparison of CD8+ cells from the intestinal lamina propria and blood 1988
    1987 Inhibition of murine lymphocyte proliferation by the B subunit of cholera toxin 1987
    1987 Deficiency of the tryptase-positive, chymase-negative mast cell type in gastrointestinal mucosa of patients with defective T lymphocyte function 1987
    1987 Collagen synthesis by human intestinal smooth muscle cells in culture 1987
    1987 Ir gene control of the murine secretory IgA response to cholera toxin 1987
    1986 Intestinal immunity and inflammation: Recent progress 1986
    1985 Genetic control of the murine immune response to cholera toxin 1985
    1985 Abnormal Accumulation of Basement Membrane (Type IV) and Cytoskeletal (Type V) Collagens in the Strictures of Crohn's Disease: The Probable Role of Intestinal Smooth Muscle Cells 1985
    1985 Genetic control of the immune response to cholera toxin 1985
    1985 Induction and control of the gastrointestinal immune system 1985
    1985 T cell-B cell regulation in the intestinal lamina propria in Crohn's disease 1985
    1984 Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen 1984
    1984 A lavage technique allowing repeated measurement of IgA antibody in mouse intestinal secretions 1984
    1984 Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen 1984
    1984 Generalized systemic and mucosal immunity in mice after mucosal stimulation with cholera toxin 1984
    1984 Hypogammaglobulinemia Due to Abnormal Suppressor T-Cell Activity in Crohn's Disease 1984
    1984 Is IgA production T cell dependent? 1984
    1984 Isolation and Culture of Human Intestinal Smooth Muscle Cells 1984
    1984 Isolation, culture and characterization of human intestinal smooth muscle cells (HISMC) 1984
    1984 This letter was shown to Dr Elson who replies as follows: 1984
    1983 Helper T cell activity in intestinal lamina propria 1983
    1983 Human host response to Giardia lamblia. II. Antibody-dependent killing in vitro 1983
    1983 T cells specific for IgA switching and for IgA B-cell differentiation 1983
    1983 T‐HELPER CELL ACTIVITY IN INTESTINAL LAMINA PROPRIA 1983
    1982 Human host response to Giardia lamblia. I. Spontaneous killing by mononuclear leukocytes in vitro 1982
    1981 Immunoregulatory function of T cells activated in the autologous mixed lymphocyte reaction 1981
    1981 Covert suppressor T cells in Crohn's disease 1981
    1981 The regulation of gastrointestinal immune responses 1981
    1980 Abnormal regulation of immunoglobulin synthesis in vitro in primary biliary cirrhosis 1980
    1980 An evaluation of total parenteral nutrition in the management of inflammatory bowel disease 1980
    1980 Deficiency of the autologous mixed lymphocyte reaction in patients with primary biliary cirrhosis 1980
    1980 Tissue distribution of IgA receptor-bearing cells in mouse and guinea pig with special reference to the lymphoid population of the gastrointestinal tract 1980
    1979 T-cell regulation of murine IgA synthesis 1979
    1979 Liver Failure With Steatonecrosis After Jejunoileal Bypass: Recovery With Parenteral Nutrition and Reanastomosis 1979
    1979 Liver failure with steatonecrosis after jejunoileal bypass 1979
    1978 Leukocytic endogenous mediator in Crohn's disease 1978
    1977 Liver failure with alcoholic like hyaline after jejuno ileal bypass; reversal by parenteral nutrition and reanastomosis 1977
    1977 Small Intestinal Injury in the Graft Versus Host Reaction: An Innocent Bystander Phenomenon 1977
    1976 Reversal of Growth Arrest in Adolescents with Crohn's Disease After Parenteral Alimentation 1976
    1975 Polymicrobial sepsis following endoscopic retrograde cholangiopancreatography 1975

    Book

    Year Title Altmetric
    1991 Mucosal Immunology I: Basic Principles. Gastro Clinics of North America.  Ed. 20.  1991
    1991 Mucosal Immunology II: Clinical Applications. Gastro Clinics of North America.  Ed. 20.  1991

    Chapter

    Year Title Altmetric
    2016 Role of the Microbiota in Immune Development.  109-119. 2016
    2010 In Vivo Models of Inflammatory Bowel Disease.  25-51. 2010
    2008 Immunologic disease of the gastrointestinal tract.  1099-1114. 2008
    2008 Microbial Sensing in the Intestine by Pattern Recognition Receptors.  33-43. 2008
    2006 Experimental mouse models of inflammatory bowel disease: New insights into pathogenic mechanisms.  67-99. 2006
    2005 Disease induction and prevention in experimental models of inflammatory bowel disease.  1237-1254. 2005
    2005 Mucosal adjuvants.  967-986. 2005
    2004 Regulatory T cells in animal models: therapeutic potential.  100-6. 2004
    2003 Are lessons from experimental models relevant for human IBD? 2003
    2001 Options in managing enteral fistulae in Inflammatory Bowel Disease.  401-4. 2001
    2000 Aetiopathogenesis 1999- How to put it all together.  133-41. 2000
    2000 Gastrointestinal diseases with an immune origin.  917-25. 2000
    2000 Induced mutant mouse models of inflammatory bowel disease: new insights into disease pathogenesis.  47-55. 2000
    2000 The Immunology of Inflammatory Bowel Disease.  208-39. 2000
    1999 Experimental models of intestinal inflammation: New insights into mechanisms of mucosal homeostasis.  1007-24. 1999
    1999 Mucosal Adjuvants.  817-38. 1999
    1998 Animal models to study molecular mechanisms underlying intestinal disease 1998
    1998 Cytokines and anti-cytokines in the therapy of inflammatory bowel disease.  232-8. 1998
    1998 Experimental models of inflammatory bowel disease: Old hypotheses confirmed and new paradigms generated.  35-42. 1998
    1998 Methotrexate and 6-mercaptopurine in chronic active Crohn’s disease - The dose is the key 1998
    1998 Principles of oral tolerance.  90-9. 1998
    1998 Role of mucosal adjuvants in mucosal immunization 1998
    1998 What can we learn from animal models?.  65-72. 1998
    1997 Basic concepts in mucosal immunology.  1-4. 1997
    1997 Genetic and chemical models of IBD. In Proc. of Falk Symposium No. 96.  21-6. 1997
    1997 Immunology.  57-66. 1997
    1997 In Defense of Mucosal Surfaces. Regulation and Manipulation of the mucosal Immune System.  373-85. 1997
    1997 Mucosal immunity and gnotobiology: Past accomplishments help point to future needs.  209-13. 1997
    1997 The effect of cholera toxin on intestinal cells and their cytokines.  83-7. 1997
    1997 Therapeutic applications of oral tolerance for human disease.  209-23. 1997
    1996 Oral Tolerance: A Commentary.  543-54. 1996
    1996 Regulation of mucosal immune responses by helper T cells and cytokines.  62-81. 1996
    1995 Experimental models of IBD: Lessons from mice.  395-400. 1995
    1995 Gastrointestinal Diseases with an Immune Basis.  525-30. 1995
    1995 Regulation of mucosal immune responses - the missing link in IBD?.  81-81. 1995
    1995 The Immunology of Inflammatory Bowel Disease.  203-51. 1995
    1995 The Mucosal Immune System.  153-62. 1995
    1994 Cytokines and Immune Mediators.  243-65. 1994
    1994 Future therapy of IBD.  17-9. 1994
    1994 Mucosal Adjuvants.  391-402. 1994
    1994 Regulation of mucosal immune responses. The missing link in IBD?.  81-7. 1994
    1993 The clinical spectrum of immune aberrations in the intestine.  146-57. 1993
    1992 Immunosuppressive drugs and methotrexate in the treatment of inflammatory bowel disease.  325-32. 1992
    1991 Cells and cytokines in mucosal immunology and inflammation.  347-66. 1991
    1991 Cholera toxin as a mucosal adjuvant.  119-32. 1991
    1991 Experimentally induced colitis in mice.  847-847. 1991
    1990 Immunosuppressive Drugs: Do they have a role in the treatment of IBD?.  235-41. 1990
    1990 Is there a primary defect in the host defense mechanism in IBD?.  59-63. 1990
    1990 Oral Immunization and Oral Tolerance.  171-82. 1990
    1990 T-Cell Activation and Inhibition by Cholera Toxin and Its B Subunit.  153-7. 1990
    1989 Cholera toxin and its subunits as potential oral adjuvants..  29-33. 1989
    1988 Gastrointestinal Diseases with an Immune Basis.  572-8. 1988
    1988 Intestinal IgA System.  349-68. 1988
    1988 Some new perspectives on IgA immunization and oral tolerance derived from the unusual properties of cholera toxin as a mucosal immunogen.  392-400. 1988
    1988 The Immunology of Inflammatory Bowel Disease.  97-164. 1988
    1987 Induction of secretory IgA responses to protein antigens..  877-885. 1987
    1983 Humoral immunoregulation in Crohn's disease.  299-299. 1983
    1982 Class-specific T cell regulation of mucosal immune response.  121-121. 1982
    1982 Endotoxin and the mucosal immune response.  73-73. 1982
    1981 Regulation of immunoglobulin synthesis in vitro in Crohn's disease: "Covert" suppressor T cells.  390-390. 1981
    1980 IgA class-specific regulatory T cells and their relationship to oral unresponsiveness.  162-162. 1980
    1979 T cell regulation of IgA synthesis.  37-37. 1979
    1978 T-cell regulation of murine IgA biosynthesis..  199-208. 1978
    Extra-articular manifestations: inflammatory bowel disease

    Principal Investigator On

  • Private Grant  awarded by CORRONA, LLC 2020 - 2025
  • An IBD Peptide Immunochip for Diagnosis, Prognosis, and Immune Monitoring in Crohn’s Disease  awarded by Rainin (Kenneth) Foundation 2019 - 2021
  • Targeting Microbiota Flagellin-Specific CD4+ Memory T Cells as a Novel Immunotherapy of Crohn's Disease  awarded by Crohn's & Colitis Foundation of America 2019 - 2020
  • UAB Multidisciplinary Clinical Research Center - Project 3  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2019
  • Targeting Microbiota Flagellin-Specific CD4+ Memory T Cells as a Novel Immunotherapy of Crohn's Disease  awarded by Crohn's & Colitis Foundation of America 2018 - 2019
  • Ulcerative Colitis Genetics Initiative  awarded by Washington University 2014 - 2017
  • Innate and Adaptive Immunity in IBD  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2010 - 2016
  • Innate and Adaptive Immunity in IBD - Administrative Core  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2010 - 2016
  • Innate and Adaptive Immunity in IBD - Animal Model Core B  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2010 - 2016
  • Innate and Adaptive Immunity in IBD - Project 1  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2010 - 2016
  • Innate and Adaptive Immunity in IBD - Project 4  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2010 - 2016
  • Ulcerative Colitis Genetics Initiative  awarded by Washington University 2014 - 2015
  • A Limited Purpose Cooperative Research and Developmental Agreement (LP-CRADA) Naval Medical Research Center  awarded by NAVAL MEDICAL RESEARCH CENTER 2013 - 2014
  • Private Grant  awarded by AMGEN, INC. 2010 - 2013
  • The Role of CBIR1 Flagellin-Specific TH17 and TH1 Effector Cells in Colitis  awarded by UNIVERSITY OF TEXAS MEDICAL BRANCH (GALVESTON) 2010 - 2011
  • Microbiota Antigens in Rheumatoid Arthritis  awarded by University of Colorado 2006 - 2011
  • TH 17Cell Regulation of Intestinal IGA Production  awarded by UNIVERSITY OF TEXAS MEDICAL BRANCH (GALVESTON) 2010
  • UAB Autoimmunity Center for Excellence  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2007 - 2009
  • UAB Autoimmunity Center for Excellence: Core A - Administrative Core  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2007 - 2009
  • UAB Autoimmunity Center for Excellence: Project 3 - Tolerance Induction to Restructure Immune Responses  awarded by National Institute of Allergy and Infectious Diseases/NIH/DHHS 2007 - 2009
  • Investigator On

  • Private Grant  awarded by THERAVANCE, INC. 2019 - 2023
  • Private Grant  awarded by Genentech 2014 - 2020
  • Private Grant  awarded by ABBVIE INC 2014 - 2020
  • Private Grant  awarded by F.Hoffmann-La Roche Ltd. 2014 - 2019
  • UAB Multidisciplinary Clinical Research Center (P60)  awarded by National Institute of Arthritis & Musculoskeletal & Skin Diseases/NIH/DHHS 2013 - 2019
  • Interactions Between AHR Ligands and the Gut Microbiota in Murine Arthritis  awarded by National Institute of Environmental Health Sciences/NIH/DHHS 2014 - 2017
  • Factors Controlling Effector T Cell Maintenance in the Pathogenesis of Colitis  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2011 - 2017
  • Altered Handling and Sensing of Xenobiotics in Inflammatory Bowel Disease  awarded by Crohn's & Colitis Foundation of America 2012 - 2014
  • Private Grant  awarded by Pfizer Pharmaceuticals 2014
  • Private Grant  awarded by Pfizer Pharmaceuticals 2014
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2009 - 2014
  • Private Grant  awarded by Centocor 2010 - 2014
  • Private Grant  awarded by Pfizer Pharmaceuticals 2011 - 2013
  • Private Grant  awarded by SCHERING PLOUGH CORPORATION 2009 - 2013
  • Mucosal HIV and Immunobiology Center  awarded by National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS 2008 - 2013
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2009 - 2013
  • Private Grant  awarded by MILLENNIUM PHARMACEUTICALS, INC. 2009 - 2013
  • Education And Training

  • Doctor of Medicine, Washington University/St. Louis 1968
  • Cornell University Medical Center, Internship 1969
  • University of Chicago Hospitals, Residency 1973
  • Cornell University Medical Center, Residency 1970
  • University of Chicago Hospitals, Postdoctoral Fellowship 1975
  • Full Name

  • Charles Elson